Effect of using 131I therapy or not after thyroidectomy in patients with intermediate-risk differentiated thyroid cancer

VernacularTitle:术后复发风险中危的分化型甲状腺癌患者 131I治疗与否对预后的影响
Author: Zhibing QI ¹ ; Tian TIAN ; Rui HUANG
Author Information

1. 四川大学华西医院核医学科，成都　610041
Keywords: Thyroid neoplasms; Recurrence; Radiotherapy; Iodine radioisotopes; Prognosis
From: Chinese Journal of Nuclear Medicine and Molecular Imaging 2023;43(6):382-384
CountryChina
Language:Chinese
Abstract: The main goal of radioactive iodine (RAI) administrated for patients with indeterminate-risk differentiated thyroid cancer (DTC) is removing occult microscopic residual disease after a total thyroidectomy, aiming to reduce recurrence and metastasis, then to improve disease-free survival. This treatment is called as adjuvant therapy, which also ablates the remnant thyroid tissue together. According to the current thyroid cancer management guidelines (2015 American Thyroid Association management guidelines), intermediate-risk patients can be selectively administered RAI. By reviewing articles about DTC patients with indeterminate-risk who underwent RAI or not after thyroidectomy, this article shows that there are inconsistent opinions on 131I decreasing recurrence and improving survival. In addition, apart from unexplained hyperthyroglobulinemia as an indication for 131I therapy, no other uniform clinicalpathological characteristics are recommended.